Volume 26, Number 3—March 2020
Research
Pregnancy Outcomes among Women Receiving rVSVΔ-ZEBOV-GP Ebola Vaccine during the Sierra Leone Trial to Introduce a Vaccine against Ebola
Figure 1

Figure 1. Enrollment and vaccination period for 84 participants in Sierra Leone Trial to Introduce a Vaccine against Ebola (STRIVE). Three participants randomized to the immediate group were unvaccinated. After vaccination, participants in the deferred group were eligible for vaccination at 18–24 weeks postenrollment. Upon vaccination, participants in the deferred group were referred to as the deferred crossover vaccinated group.
1These first authors contributed equally to this article.
2These authors were co–principal investigators.